Evidence map›Paper›PMID 37753974›Full record

ArticleAntibodies (Basel, Switzerland)2023

Comparison between Neutralization Capacity of Antibodies Elicited by COVID-19 Natural Infection and Vaccination in Indonesia: A Prospective Cohort.

Sitti Nurisyah, Mitsuhiro Iyori, Ammar Abdurrahman Hasyim, Akihiko Sakamoto, Hinata Hashimoto, Kyouhei Yamagata, Saya Yamauchi, Khaeriah Amru, Kartika Hardianti Zainal, Irfan Idris and 6 more

Open access · goldAbstract read
In one paragraph

Article in Antibodies (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Evaluation of anNarra J · 2025
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Sitti NurisyahFaculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia.ORCID 0000-0003-2285-7286
Mitsuhiro IyoriResearch Institute of Pharmaceutical Sciences, Musashino University, Nishitokyo, Tokyo 202-8585, Japan.ORCID 0000-0001-9940-7342
Ammar Abdurrahman HasyimLaboratory of Vaccinology and Applied Immunology, Kanazawa University, Kanazawa 920-1192, Japan.ORCID 0000-0003-2799-1652
Akihiko SakamotoLaboratory of Vaccinology and Applied Immunology, Kanazawa University, Kanazawa 920-1192, Japan.ORCID 0000-0003-0788-3646
Hinata HashimotoLaboratory of Vaccinology and Applied Immunology, Kanazawa University, Kanazawa 920-1192, Japan.
Kyouhei YamagataLaboratory of Vaccinology and Applied Immunology, Kanazawa University, Kanazawa 920-1192, Japan.
Saya YamauchiLaboratory of Vaccinology and Applied Immunology, Kanazawa University, Kanazawa 920-1192, Japan.
Khaeriah AmruFaculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia.
Kartika Hardianti ZainalLaboratory of Vaccinology and Applied Immunology, Kanazawa University, Kanazawa 920-1192, Japan.
Irfan IdrisFaculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia.ORCID 0000-0002-7350-8687
Shigeto YoshidaLaboratory of Vaccinology and Applied Immunology, Kanazawa University, Kanazawa 920-1192, Japan.
Irawaty DjaharuddinFaculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia.ORCID 0000-0002-5240-4950
Din SyafruddinFaculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia.
Agussalim BukhariFaculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia.ORCID 0000-0002-6340-8615
Puji Budi Setia AsihBadan Riset dan Inovasi Nasional (National Research and Innovation Agency), Jakarta 10340, Indonesia.
Yenni YusufFaculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia.ORCID 0000-0001-7310-6381
Hasanuddin University · IDKanazawa University · JPMusashino University · JPNational Nuclear Energy Agency of Indonesia · ID

Funding

DGHE or DIKTI 105/E4.4/KU/2021Hasanuddin University 915/UN4.22/PT.01.03/2021Japan Society for the Promotion of Science JPJSBP-120218101
6 · The paper itself

Abstract

backgroundTo fight the COVID-19 pandemic, immunity against SARS-CoV-2 should be achieved not only through natural infection but also by vaccination. The effect of COVID-19 vaccination on previously infected persons is debatable.

methodsA prospective cohort was undergone to collect sera from unvaccinated survivors and vaccinated persons-with and without COVID-19 pre-infection. The sera were analyzed for the anti-receptor binding domain (RBD) titers by ELISA and for the capacity to neutralize the pseudovirus of the Wuhan-Hu-1 strain by luciferase assays.

resultsNeither the antibody titers nor the neutralization capacity was significantly different between the three groups. However, the correlation between the antibody titers and the percentage of viral neutralization derived from sera of unvaccinated survivors was higher than that from vaccinated persons with pre-infection and vaccinated naïve individuals (Spearman correlation coefficient (

conclusionsVaccines induce anti-RBD titers as high as the natural infection with lower neutralization capacity, and it does not boost immunity in pre-infected persons.

Indexed as

COVID-19natural infectionneutralizing antibodiesreceptor binding domain (RBD)vaccination

Identifiers

PMID37753974
PMCPMC10526084
OpenAlexW4386929511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.